

VPA10454/035/001

**Eprivalan 5mg/ml pour-on solution for cattle**

<b>Variation</b>	<b>Summary</b>	<b>Date</b>
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	07/07/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	07/07/23
Vet - B10 b)	VNRA - Vet - B10 b) - b) Addition of a new in-process test and limits - B10 b) Changes to the quality part of the dossier: Change to in-process tests or limits applied during the manufacture of the active substance —addition of a new in-process test and limits	27/10/22
Vet - A1 a)	VNRA - Vet - A1 a) - a) Change in the name or address or contact details of the marketing authorisation holder - A1 a) Administrative changes: Change in the name or address or contact details of the marketing authorisation holder	08/08/22
Vet - B3 e)	VNRA - Vet - B3 e) - e) Deletion of a test procedure - B3 e) Changes to the quality part of the dossier: Deletion of a test procedure — for the active substance or a starting material, reagent or intermediate of the active substance; —for the immediate packaging of the active substance; — for an excipient or the finished product; —for the immediate packaging of the finished product	28/07/22
Vet - B12 b)	VNRA - Vet - B12 b) - b) Minor changes to an approved test procedure (starting material, excipient) - B12 b) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	28/07/22
A.4	IA - A.4 - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - A.4 - ADMINISTRATIVE CHANGES - Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or	15/03/22

	intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier)	
--	---	--